tradingkey.logo

Sol Gel Technologies Ltd

SLGL
65.780USD
+1.080+1.67%
종가 02/06, 16:00ET시세는 15분 지연됩니다
183.25M시가총액
손실P/E TTM

Sol Gel Technologies Ltd

65.780
+1.080+1.67%

자세한 내용은 Sol Gel Technologies Ltd 회사

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

Sol Gel Technologies Ltd 정보

종목 코드 SLGL
회사 이름Sol Gel Technologies Ltd
상장일Feb 01, 2018
CEO- -
직원 수34
유형Ordinary Share
회계 연도 종료Feb 01
주소Golda Meir 7
도시NESS-ZIONA
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Israel
우편 번호- -
전화97289313433
웹사이트http://www.sol-gel.com
종목 코드 SLGL
상장일Feb 01, 2018
CEO- -

Sol Gel Technologies Ltd의 회사 임원진

이름
이름/직위
직위
주식 보유
변동
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+105123.00%
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Dr. Itzik Yosef, Ph.D.
Dr. Itzik Yosef, Ph.D.
Vice President - Operations
Vice President - Operations
--
--
Dr. Dubi (Dov) Zamir, Ph.D.
Dr. Dubi (Dov) Zamir, Ph.D.
Vice President - Special Projects
Vice President - Special Projects
--
--
Mr. Itai Arkin
Mr. Itai Arkin
Director
Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Ms. Hani Lerman
Ms. Hani Lerman
Director
Director
--
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+105123.00%
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Dr. Itzik Yosef, Ph.D.
Dr. Itzik Yosef, Ph.D.
Vice President - Operations
Vice President - Operations
--
--
Dr. Dubi (Dov) Zamir, Ph.D.
Dr. Dubi (Dov) Zamir, Ph.D.
Vice President - Special Projects
Vice President - Special Projects
--
--

수익 분석

기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.

주식 보유 통계

마지막 업데이트: Fri, Feb 6
마지막 업데이트: Fri, Feb 6
주주
주주 유형
주주
주주
비율
M.Arkin Dermatology, Ltd.
64.86%
Opaleye Management Inc.
13.78%
Phoenix Investment and Finances Ltd
7.83%
Arkin (Moshe)
5.14%
Yelin Lapidot Provident Funds Management Ltd
0.64%
기타
7.75%
주주
주주
비율
M.Arkin Dermatology, Ltd.
64.86%
Opaleye Management Inc.
13.78%
Phoenix Investment and Finances Ltd
7.83%
Arkin (Moshe)
5.14%
Yelin Lapidot Provident Funds Management Ltd
0.64%
기타
7.75%
주주 유형
주주
비율
Corporation
64.86%
Hedge Fund
13.78%
Investment Advisor
8.54%
Individual Investor
5.14%
Insurance Company
0.27%
Research Firm
0.16%
Investment Advisor/Hedge Fund
0.05%
기타
7.20%

기관 주식 보유

마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
35
617.10K
22.15%
-504.63K
2025Q3
35
286.02K
10.27%
-480.14K
2025Q2
36
2.50M
89.88%
-104.83K
2025Q1
37
2.45M
84.60%
+78.00K
2024Q4
35
23.50M
84.37%
-314.30K
2024Q3
34
23.55M
84.52%
-115.49K
2024Q2
31
25.52M
91.61%
+1.51M
2024Q1
30
23.87M
85.67%
+1.61M
2023Q4
31
22.12M
83.66%
-222.95K
2023Q3
30
22.20M
83.99%
-4.35K
더 보기

주주 활동

이름
보유 주식
비율
변동
Chg %
날짜
M.Arkin Dermatology, Ltd.
1.81M
64.86%
--
--
Jun 11, 2025
Opaleye Management Inc.
383.58K
13.77%
+10.43K
+2.80%
Dec 17, 2025
Phoenix Investment and Finances Ltd
218.22K
7.83%
-28.80K
-11.66%
Sep 30, 2025
Arkin (Moshe)
143.26K
5.14%
+105.12K
+275.67%
Jun 11, 2025
Menora Mivtachim Insurance Ltd.
7.61K
0.27%
+7.61K
--
Sep 30, 2025
Morgan Stanley & Co. LLC
4.37K
0.16%
-970.00
-18.18%
Sep 30, 2025
Steward Partners Investment Advisory, LLC
316.00
0.01%
--
--
Sep 30, 2025
더 보기

관련 ETF

마지막 업데이트: Tue, Dec 2
마지막 업데이트: Tue, Dec 2
이름
비율
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
비율0%

주식 배당금

지난 5년 동안 총 0.00 USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음

주식 분할

날짜
배당락일
유형
비율
May 01, 2025
Merger
10→1
날짜
배당락일
유형
비율
May 01, 2025
Merger
10→1
KeyAI